Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

RGEN
Repligen Corp
stock NASDAQ

At Close
Jul 16, 2026 3:59:59 PM EDT
148.52USD+0.311%(+0.46)834,859
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 15, 2026 8:08:30 AM EDT
146.05USD-1.358%(-2.01)0
After-hours
Jul 15, 2026 4:02:30 PM EDT
148.06USD-0.041%(-0.06)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 30, 2021
07:30AM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40thAnnual J.P. Morgan Healthcare conference being held January 10-13. Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST.   GlobeNewswire Inc
Nov 12, 2021
07:30AM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences.   GlobeNewswire Inc
Nov 5, 2021
07:30AM EDT  Repligen Releases Inaugural Sustainability Report   GlobeNewswire Inc
Oct 29, 2021
05:31AM EDT  SVB Leerink Maintains Outperform on Repligen, Raises Price Target to $325   Benzinga
Oct 28, 2021
08:26AM EDT  The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug   Benzinga
07:53AM EDT  Repligen Raises FY21 Sales Guidance From $625M-$645M To $655M-$665M vs $640.61M Est.   Benzinga
07:50AM EDT  Repligen Q3 Adj. EPS $0.78 Beats $0.64 Estimate, Sales $178.20M Beat $163.97M Estimate   Benzinga
07:30AM EDT  -- Reports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77% -- Raises revenue guidance to $655-$665 million for full year 2021 -- Completes acquisition of affinity ligands innovator Avitide Inc.   GlobeNewswire Inc
04:08AM EDT  Earnings Scheduled For October 28, 2021   Benzinga
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 14, 2021
11:18AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021   Benzinga
07:30AM EDT  Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT   GlobeNewswire Inc
07:04AM EDT  Exane BNP Paribas Initiates Coverage On Repligen with Outperform Rating, Announces Price Target of $330   Benzinga
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 27, 2021
08:55AM EDT  Craig-Hallum Maintains Buy on Repligen, Raises Price Target to $368   Benzinga
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 22, 2021
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 17, 2021
10:59AM EDT  UPDATE: KeyBanc On Repligen Price Target Raise: Firm Sees Co. 'Quickly Reducing Its Proteins Risk' Given Recent Cytiva Contract Extension & Successful Launches Of Navigo Ligands & Purolite Resins   Benzinga
10:58AM EDT  UPDATE: KeyBanc On Repligen Price Target Raise: Firm Highlights $150M Acquisition Of Avitide For Exposure To Affinity Ligands Production Used In The Purification Of Viral Vectors For Gene Therapies   Benzinga
07:39AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
04:36AM EDT  Keybanc Maintains Overweight on Repligen, Raises Price Target to $335   Benzinga
Sep 16, 2021
01:08PM EDT  Repligen Reinforces Proteins Business With $150M Avitide Acquisition Deal   Benzinga
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
07:44AM EDT  Repligen To Acquire Avitide For $150M   Benzinga
07:41AM EDT  -- Proposed acquisition strengthens Repligens Proteins business   GlobeNewswire Inc
Sep 9, 2021
07:37AM EDT  Repligen And Navigo GmbH Announce Launch Of Industry-First Protein A Ligand for Purification Of pH Sensitive Antibodies   Benzinga
07:30AM EDT  Repligen and Navigo GmbH Announce Launch of   GlobeNewswire Inc
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 25, 2021
07:30AM EDT  The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug   Benzinga
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Jul 29, 2021
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 27, 2021
11:13AM EDT  Recap: Repligen Q2 Earnings   Benzinga
11:13AM EDT  Repligen Raises FY21 EPS Guidance From $2.21-$2.28 To $2.71-$2.78 Vs. $2.25 Est., Sales Guidance From $565M-$590M To $625M-$645M Vs. $585.9M Est.   Benzinga
11:13AM EDT  Repligen Q2 EPS $0.79 Beats $0.52 Estimate, Sales $163.00M Beat $144.10M Estimate   Benzinga
04:03AM EDT  Earnings Scheduled For July 27, 2021   Benzinga
Jul 26, 2021
10:37AM EDT  Earnings Outlook For Repligen   Benzinga
Jun 22, 2021
07:20AM EDT  Repligen To Buy Polymem For An Undisclosed Sum   Benzinga
06:39AM EDT  Repligen Announces Agreement To Acquire Polymem   RTTNews
06:30AM EDT  Repligen Corporation Announces Agreement To Acquire Polymem S.A.; Size Of Deal Not Disclosed   Benzinga
06:30AM EDT  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Toulouse, France based Polymem S.A. (Polymem), a leading industrial expert in the development and manufacture of hollow fiber membranes and modules.   GlobeNewswire Inc
May 25, 2021
07:30AM EDT  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences.   GlobeNewswire Inc
May 5, 2021
06:26AM EDT  HC Wainwright & Co. Maintains Buy on Repligen, Raises Price Target to $240   Benzinga
May 4, 2021
10:08AM EDT  Repligen shares were trading higher after the company reported better-than-expected Q1 EPS and sales results. The company raised FY21 EPS and sales guidance above estimates.   Benzinga
08:14AM EDT  Repligen: Q1 Earnings Insights   Benzinga
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
07:42AM EDT  Repligen Raises FY21 Sales Guidance From $500M-$525M To $565M-$590M Vs. $513.38M Est., Raises FY21 EPS Guidance From $1.86-$1.94 To $2.21-$2.28 Vs. $1.91 Est.   Benzinga
07:40AM EDT  Repligen Q1 EPS $0.68 Beats $0.42 Estimate, Sales $142.80M Beat $117.01M Estimate   Benzinga
07:30AM EDT  -- Reported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69% -- Growth driven by combination of COVID-related demand, base business strength and acquisition revenue   GlobeNewswire Inc
Apr 20, 2021
07:30AM EDT  Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2021 financial results on Tuesday, May 4, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2021.   GlobeNewswire Inc
Apr 12, 2021
07:45AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:36AM EDT  HC Wainwright & Co. Reiterates Buy on Repligen, Raises Price Target to $225   Benzinga
Mar 17, 2021
07:30AM EDT  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 23-24. Tony Hunt, President & Chief Executive Officer, will participate in a fireside chat on Wednesday, March 24, at 9:15 a.m. EDT.   GlobeNewswire Inc
Mar 3, 2021
07:30AM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST.   GlobeNewswire Inc
Feb 25, 2021
07:55AM EST  10 Biggest Price Target Changes For Thursday   Benzinga
05:19AM EST  SVB Leerink Maintains Outperform on Repligen, Raises Price Target to $250   Benzinga
Feb 24, 2021
07:48AM EST  Repligen: Q4 Earnings Insights   Benzinga
07:38AM EST  Repligen Sees FY 2021 Adj. EPS $1.86-$1.94 Vs $1.65 Est.   Benzinga
07:37AM EST  Repligen Sees FY 2021 Revs. $500M-$525M Vs $459.53M Est.   Benzinga
07:33AM EST  Repligen Q4 EPS $0.52 Beats $0.31 Estimate, Sales $108.60M Beat $93.88M Estimate   Benzinga
07:30AM EST  -- Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growth -- Organic revenue growth was 47% for the fourth quarter and 29% for the year 2020   GlobeNewswire Inc
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
03:35AM EST  Earnings Scheduled For February 24, 2021   Benzinga
Feb 22, 2021
07:30AM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10thAnnual SVB Leerink Healthcare conference being held February 22-26. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST.   GlobeNewswire Inc
Feb 11, 2021
03:00PM EST  Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST   GlobeNewswire Inc
Feb 8, 2021
07:39AM EST  Repligen, Says Co, Navigo Proteins Announce Launch Of Affinity Resin For Purification Of COVID-19 Vaccines   Benzinga
07:38AM EST  Repligen and Navigo Proteins Announce the Launch of an Affinity   GlobeNewswire Inc
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 4, 2021
01:00PM EST  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 39thAnnual J.P. Morgan Healthcare conference being held January 11-14. Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Wednesday, January 13, at 9:10 a.m. EST.   GlobeNewswire Inc
Dec 30, 2020
10:24AM EST  P/E Ratio Insights for Repligen   Benzinga
Dec 10, 2020
04:18PM EST  Repligen Corporation Announces Closing of Public Offering of   GlobeNewswire Inc
Dec 8, 2020
12:21PM EST  EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen   PR Newswire
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
09:41PM EST  Repligen Corporation Prices Public Offering of Shares of Common Stock   GlobeNewswire Inc
07:36AM EST  Repligen Begins Public Offering Of 1.5 Mln Shares Of Its Common Stock   RTTNews
07:23AM EST  Repligen Announces 1.5M Share Offering   Benzinga
07:22AM EST  Repligen Corporation Announces Proposed Public Offering of Shares   GlobeNewswire Inc
Nov 16, 2020
09:51AM EST  Return On Capital Employed Overview: Repligen   Benzinga
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Nov 5, 2020
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
07:53AM EST  Repligen Raises FY20 EPS Guidance From $1.24-$1.29 To $1.41-$1.45 Vs. $1.28 Est., Sales From $332M-$340M To $348M-$352M Vs. $337.53M Est.   Benzinga
07:51AM EST  Repligen Q3 EPS $0.40 Beats $0.28 Estimate, Sales $94.06M Beat $86.45M Estimate   Benzinga
07:30AM EST  Repligen Reports Third Quarter 2020 Financial Results and Updates   GlobeNewswire Inc
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 27, 2020
04:43PM EDT  Reokigen Announces An Agreement To Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions For Roughly $200M   Benzinga
04:15PM EDT  Repligen Corporation Announces Agreement to Acquire Bioprocess   GlobeNewswire Inc
08:25AM EDT  The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings   Benzinga
Oct 22, 2020
07:30AM EDT  - Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST -   GlobeNewswire Inc
Oct 1, 2020
06:36AM EDT  Repligen And Navigo Proteins GmbH Announce Development Of Affinity Ligand Targeting Spike Protein   RTTNews
06:36AM EDT  Repligen And Navigo Proteins Announces Their Achievement Of A Key Milestone In Developing An Affinity Resin For The Purification Of Coronavirus Vaccines   Benzinga
06:30AM EDT  Repligen and Navigo Proteins Announce Achievement of Key Milestone   GlobeNewswire Inc
Sep 14, 2020
07:01AM EDT  Repligen and Sanofi Receive Breakthrough Therapy Designation for Dupixent   Benzinga
Aug 24, 2020
08:21AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:09AM EDT  HC Wainwright & Co. Maintains Buy on Repligen, Raises Price Target to $168   Benzinga
Jul 30, 2020
07:39AM EDT  Repligen Raises FY20 Adj. EPS From $1.09-$1.14 To $1.24-$1.29 vs $1.13 Est., Raises FY20 Sales Guidance From $309M-$319M To $332M-$340M vs $317.04M Est.   Benzinga
07:37AM EDT  Repligen Q2 Adj. EPS $0.42 Beats $0.27 Estimate, Sales $87.50M Beat $78.38M Estimate   Benzinga
07:30AM EDT  -- Reports record quarterly revenue of $87.5 million -- Overall revenue grew 24% year-over-year, with organic growth of 19% -- Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth -- Completes acquisition of silicone molding and tubing manufacturer Engineered Molding Technology   GlobeNewswire Inc
04:06AM EDT  Earnings Scheduled For July 30, 2020   Benzinga
Jul 15, 2020
07:30AM EDT  Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2020 financial results on Thursday, July 30, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2020.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC